Pages Menu
TwitterRssFacebook
ISSN (Online): 2454-1680

OncoExpert

INTERNATIONAL JOURNAL OF INTEGRATED ONCOLOGY

An Official Publication Of Society Of Pharmaceutical Science & Research
Categories Menu

Most Cited

 
Title
Views
PDF
Cited
1.

IMPACT OF CHRONOMODULATED RADIOTHERAPY ON ACUTE SKIN TOXICITY IN CHEST WALL IRRADIATED BREAST CANCER PATIENTS – A SINGLE INSTITUTION ANALYSIS.

Abstract: We explored the possible association between the timing of delivery of radiation and the grade of skin reaction that develops in breast cancer patients receiving chest wall irradiation as adjuvant treatment after modified radical mastectomy. Invasive breast cancer patients, registered during the period of January 2013 – December 2014, who had undergone modified radical mastectomy followed by chest wall irradiation, were eligible for inclusion to the study. All the patients received chest wall external beam radiotherapy (EBRT) to a dose of 50 Gy in 25 fractions, one fraction a day, five days a week, delivered as tangential opposed pair, from a Cobalt 60 teletherapy source. Patients were stratified based on whether they received EBRT in the morning (between 8 am – 11 am) or in the evening between (5 pm – 8 pm). The clinicopathological characteristics of patients in both the arms were relatively well balanced. The incidence of higher grade of skin reaction (grade 3 or 4) was 22.5 % compared to 35.7 % in the morning and evening arms respectively, which was statistically significant (p = 0.039). The time to development of Grade 3 or 4 toxicity was 4.44 weeks compared to 4.11 weeks in the morning and evening arms respectively, suggesting that higher toxicity developed earlier in the patients receiving EBRT in the evening, though not statistically significant (p =...

Vipin George Kuriakose, Krishnanannair Jayakumar, Aravindh Anand, Anand Radha Krishnan, Divya Somasekharan

Dr. Vipin George Kuriakose, Department of Radiotherapy and Oncology, Government Medical College, Thiruvananthapuram INDIA

DOI:

1-7

1073

491

0

6.

PRIMARY NON-HODGKIN LYMPHOMA OF LIVER: AN UNUSUAL PRESENTATION AND REVIEW OF ITS MANAGEMENT.

 Primary Non-Hodgkin lymphoma (NHL) of liver is a very rare malignancy. Here, we report a case of 26 years old man who presented with right upper abdomen pain and lump, reduced appetite and progressive weakness of 4 month’s duration. Liver functions were deranged but serology was negative for viral markers and α Fetoprotein was within normal range. Ultrasonography and Computed Tomography scan of the abdomen revealed large nodule in right lobe of the liver. USG guided biopsy of liver mass and fluorescence in situ hybridization for CD markers established diagnosis of primary NHL of liver. Extensive investigations including X-ray of chest, whole-body positron-emission tomography scan and bone marrow biopsy showed no involve­ment of mediastinum, spleen, bone marrow or any other organ or lymph nodes significantly. Having B symptoms disease was staged IVB, the patient has been treated with 6 cycles of R-CHOP regimen (Rituximab/Cyclophosphamide–Doxorubicin–Vincristine–Prednisolone) followed by 2 courses of CHOP every three weekly. Response has been excellent and patient is asymptomatic as of now. This case highlights that primary hepatic lymphoma should be considered in the differential diagnosis of space-occupying liver lesions in presence of normal levels of...

Mukesh Kumar Bharti, Sudhakar Singh

Dr. Mukesh Kumar Bharti Assistant Professor, Dept of Radiotherapy & Oncology DMCH Laheriasarai, Darbhanga, Bihar

DOI:

35-39

918

545

0

2.

OUTCOMES OF LOCALLY ADVANCED RETROMOLAR TRIGONE CANCERS TREATED WITH A MULTIMODALITY APPROACH

Our objective is to review the current articles pertaining to multimodality treatment that surround the management of retromolar trigone (RMT) cancer patients. RMT tumors constitute a small minority of all oral cancers. Majority of these patients present with locally advanced stage and its treatment is challenging. Good oncologic outcomes can be achieved by advocating an aggressive surgical approach in combination with post operative radiation therapy. In this literature review we intend to discuss locally advanced trigone cancer and its outcome after the completion of the multimodality...

Ashwin A Kallianpur, Vinod Nimbran, Romeeta Trehan, Shweta Mittal

Dr Ashwin A Kallianpur Senior Consultant, Department of Surgical Oncology, Indus Superspeciality Hospital, Mohali, INDIA

DOI:

8-14

1048

519

0

5.

UNUSUAL PRESENTATION OF NON-HODGKIN LYMPHOMA: VULVA GROWTH AND BREAST MASS IN THE SAME PATIENT

Primary involvement of vulva or breast by non-hodgkin lymphoma (NHL) is known to occur uncommonly. Only 24 cases of NHL vulva and around 250 cases of NHL breast alone have been reported, so far; but none with simultaneous involvement of the two sites together. We report the first case having both sites involved in a 35 year old Indian female.

Yashpal Verma, Ashok K. Chauhan, Ramesh Sabharwal and Jagjeet Singh

Dr. Yashpal Verma, Medical Officer, Department of Radiotherapy, University of Health Sciences, Rohtak (INDIA). Contact no. +91-9416125026

DOI:

31-34

1130

565

0

4.

PRIMARY ANAPLASTIC LARGE CELL LYMPHOMA OF BONE: MANAGING THE MISCELLANEOUS!

Anaplastic large cell lymphoma (ALCL) represents 2 to 3% of non-Hodgkin lymphoma (NHL). Anaplastic lymphoma kinase negative (ALK-) subtype accounts for 15-50% of all ALCL. Primary bone involvement in lymphoma is uncommon and constitutes less than 1% of all lymphomas and 4-5% of all extranodal NHL. Hence extra-nodal primary bone involvement in ALCL is even rarer. We report the 14th case of primary ALCL in a 38 year old Indian female. Other than the uncommon site, there is no reason not to keep NHL as differential diagnosis, as the condition responds too well to standard...

Sulbha Mittal, Yashpal Verma, Ashok K. Chauhan, Paramjeet Kaur, Anil Khurana, Nupur Bansal

Medical Officer, Department of Radiotherapy, University of Health Sciences, Rohtak (INDIA)

DOI:

25-29

896

575

0

1.

CANCER CHRONOTHERAPY: THE RIGHT TIME TO HIT!

Chronomodulated therapy or chronotherapy has gained popularity, beyond a fancy term, as a novel and logical method to exploit the best, by administering anti-cancer treatment at an optimal timing according to circadian rhythms of their anti-cancer action and/or repair mechanism of cancer & normal cells. Understanding of chronobiology and the results of clinical studies back up this new concept. Chronotherapy seems to have all the potential to become tomorrow’s accepted, refined oncology practice without adding much to the cost of existing...

Ashok Kumar Chauhan, Yashpal Verma and Ramesh Sabharwal

Dr Yashpal Verma, Medical Officer, Department of Radiotherapy, Post graduate institute of medical sciences, Rohtak (INDIA)

DOI:

1-7

1179

747

0

3.

CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY: METHODS TO MEASURE

Peripheral neuropathy is a structural or functional abnormality of peripheral nerves giving rise to neuropathic symptoms. Neuropathic symptoms can be motor, sensory and autonomic or varied combination of these major categories. Chemotherapeutic agents frequently cause various neuropathic symptoms and signs depending upon culprit agent, its dose and duration. Chemotherapy-Induced Peripheral Neurotoxicity is a common, disabling and dose-limiting side-effect of cancer treatment and its assessment is difficult. Some patients complain of tingling, numbness and pain in distal extremities while others may also develop motor and autonomic symptoms. Some patients remain symptomatic even after discontinuation of offending drugs. Patients with chemotherapy induced neuropathy bear higher healthcare cost than cancer patients without neuropathy. As new chemotherapeutic agents are being developed it is important to measure chemotherapy induced peripheral neuropathy accurately so that it can be recognized at an earlier stage, the treatment can be modified appropriately and disease progression can be monitored. An added advantage would be a possibility of reliable comparison between neuropathic side effect of newer and older chemotherapeutic...

Ravi Uniyal

Senior Resident, Department of Neurology, SGPGI, Lucknow, INDIA

DOI:

15-23

1047

0

0

2.

INTENSITY MODULATED RADIATION THERAPY: OVERVIEW OF JOURNEY FROM CONVENTIONAL TO DASSIM-RT

Intensity modulated radiation therapy (IMRT) is a technique to deliver a highly conformal radiation dose distribution, that too with wide spectrum ranging from conventional IMRT, through Volumetric Modulated Arc Therapy (VMAT) to most advanced form called Dense Angularly Sampled and Sparse Intensity Modulated Radiation Therapy (DASSIM-RT). The article intends to overview the current status of the technology....

Yogesh Kumar, Ashok Kumar Chauhan, Nagappan Balasubramanian, Narayan Parshad Patel and Yashpal Verma

Yogesh Kumar, Physicist, Department of Radiotherapy, Post-graduate institute of medical sciences, Rohtak (INDIA) - 124001. Mobile: +91-9416357357

DOI:

8-13

1257

506

0

3.

PRIMARY RENAL LYMPHOMA: A RARE CASE REPORT

Primary renal Non-hodgkin lymphoma is rare. Most of the cases are unilateral though bilateral cases have been reported. Extrarenal involvement is to be excluded by imaging/ staging laprotomy for definitive diagnosis. We are presenting a case of 40-year-old Indian female who was attended with history of right flank pain for 3 years, found to have right renal mass on CT scan, underwent right radical nephrectomy and six courses of chemotherapy with CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone) regimen subsequent to histo-pathological confirmation. Patient is asymptomatic on follow up of 18...

Mukesh Kumar, Paramjeet Kaur, Yashpal Verma, Anil Khurana, Nupur Bansal, Ashok K Chauhan

Department of Radiotherapy, Pt. BDS PGIMS Rohtak INDIA

DOI:

16-19

893

157

0

3.

ROLE OF COENZYME Q10 IN CURRENT ONCOLOGY PRACTICE: SUBSTANCE OR SHADOW!

CoQ10 tissue levels. CoQ10 therapy has no serious side effects in humans and new formulations have been developed that increase CoQ10 absorption and tissue distribution. CoQ10 has a role in carcinoma breast, cervix, lung, prostate, melanoma, cancer chemotherapy and cancer related fatigue. Future trends involving CoQ10 in many cancers needs more clinical trials for better understanding of CoQ10 efficacy.. Oral CoQ10 administration can correct CoQ10 deficiency since it increases CoQ10 tissue levels. CoQ10 therapy has no serious side effects in humans and new formulations have been developed that increase CoQ10 absorption and tissue distribution. CoQ10 has a role in carcinoma breast, cervix, lung, prostate, melanoma, cancer chemotherapy and cancer related fatigue. Future trends involving CoQ10 in many cancers needs more clinical trials for better understanding of CoQ10...

Abhishek Soni, Monica Verma, Sumeet Aggarwal, Vivek Kaushal and Yashpal Verma

Dr Abhishek Soni, Senior Resident, Department of Radiotherapy, Post-graduate Institute Of Medical Sciences, Rohtak (INDIA) - 124001

DOI:

14-22

1253

931

0

Page 1 of 212